Lyophilized BPC 157 stores best sealed, desiccated, dark and at minus 20 °C, with refrigerated working stock acceptable over defined windows. Once dissolved it becomes a dated, refrigerated solution measured in days, or frozen single-use aliquots. The compound's stability reputation comes from gastric-juice experiments and says nothing about a vial on a bench.
- BPC 157 is a fifteen-residue synthetic peptide whose sequence contains none of the residues most prone to oxidation or deamidation.
- The gastric-juice stability reported in the originating literature is a claim about acid and enzyme resistance in one experimental context, not shelf-life data.
- Dry, sealed, desiccated storage at minus 20 °C is the slowest degradation regime; water is the variable that matters most.
- No USP/NF monograph exists for BPC 157, so supplier stability figures are conventions unless a lot-specific study stands behind them.
- Concentration arithmetic differs on a gross-mass versus net-peptide-content basis, and a preparation record should state which one it used.
- The FDA placed BPC 157 in Category 2 of the 503A bulks list effective 29 September 2023 and removed it in April 2026 without adding it to Category 1.
Where the stability reputation comes from
BPC 157 has a reputation as the peptide that shrugs off bad handling. The reputation has a real origin. The preclinical literature that introduced the compound, from the Zagreb group that has published on it since the early 1990s, describes it as stable in human gastric juice for 24 hours or more, and for a peptide that is an unusual property. It gets repeated in nearly every secondary description of the molecule.
Read what the claim actually covers. Stability in gastric juice is a statement about resistance to acid and digestive enzymes, in solution, in one experimental context, reported by the group with the most invested in the molecule. It is not shelf-life data. It says nothing about a lyophilized cake sitting in a vial for eight months, nothing about what light and oxygen do over time, and nothing about a prepared solution on its fourth week in a refrigerator door.
There is also no compendial monograph for BPC 157, so no official document defines what acceptable material is or how long it keeps. The figures on this page come from general lyophilized-peptide stability science and from supplier stability programs, and they should be read that way. The sibling storage and stability guide covers the general chemistry at length; this page covers what is specific to this sequence.
What fifteen residues rule out, and what they leave in
BPC 157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular mass close to 1419 daltons for the free peptide; PubChem carries the record. Research suppliers typically ship it as an acetate salt, which matters for the arithmetic later on this page. The sequence is short, has no disulfide chemistry, and is heavy on proline, which occupies four of the fifteen positions.
Run the standard degradation routes against that sequence and a pattern shows up.
| Route | Requires | Present in this sequence? | Remaining relevance |
|---|---|---|---|
| Oxidation | Methionine, cysteine or tryptophan; light, oxygen, trace metals | None of the three residues | Low for the dry solid; store dark anyway |
| Deamidation | Asparagine or glutamine plus water | Neither residue | Structurally unavailable |
| Aspartate isomerization | Aspartate residues, water, time | Asp at positions 10 and 11 | The main slow chemical route once in solution |
| Backbone hydrolysis | Water | Every amide bond | The reason dry storage is the whole game |
| Aggregation | Interfaces, agitation, concentration | Possible for any peptide; no lipid anchor here | Swirl rather than shake; avoid foaming a solution |
The absences are the kernel of truth in the reputation. The classic oxidation targets are missing from the sequence, and so are the residues that make deamidation the headline failure mode for many peptides. What remains is backbone hydrolysis, which needs nothing more exotic than water, and isomerization at the Asp-Asp pair in the middle of the chain, a slow rearrangement that a good RP-HPLC method resolves as a closely eluting extra peak. Aggregation stays possible in solution, as it does for any peptide, though without a fatty-acid anchor this molecule is far less interface-active than a lipidated compound like tirzepatide.
The practical conclusion runs one way only. A sequence with fewer failure routes fails more slowly under the same conditions. It does not fail never, and none of its resistances apply to a vial with water in it.
Storage conditions by physical state
| State | Condition | Relative horizon | Why |
|---|---|---|---|
| Sealed powder, long term | Minus 20 °C or below, desiccated, dark | Longest | Water is excluded and every remaining route is slowed |
| Sealed powder, working stock | 2 to 8 °C, dark | Shorter than frozen | Defensible where the vial is used inside a defined, recorded window |
| Powder in transit | Ambient, insulated, dark | Days | A dry solid tolerates short excursions far better than any solution |
| Prepared solution | 2 to 8 °C, dark, dated | Days, not months | Hydrolysis has water to work with; contamination has a medium |
| Solution, single-use aliquots | Minus 20 °C or below | Longer, at a cost per thaw | Freeze-thaw aggregation is cumulative and invisible |
The horizons are deliberately relative. Pinning a number of months on a research powder would take stability data generated on that lot, in that container, under those conditions, and for a compound with no monograph nobody is obliged to have generated any. A supplier quoting a confident figure without a study behind it is quoting a convention. The lot's own certificate is the only document entitled to carry a date, and where it carries none, the window is unestablished and the record should say so in those words.
One habit transfers from vial to vial regardless of compound: the marker pen. Date the powder vial at first entry, date the solution at preparation, date every aliquot. An undated container cannot be trusted at any age, and replacing one costs more patience than ink.
The handling errors the reputation invites
The most common storage failure with this compound is not chemical, it is behavioural. A material described everywhere as stable gets handled as if it were indestructible, and two habits do most of the damage.
The first is opening a vial straight from the freezer. Cold glass sits below the dew point of room air, moisture condenses onto every surface it can reach, and the inside of the vial joins that list the moment the seal breaks. A lyophilized cake takes the water up with no change in appearance, then goes back to the freezer carrying it. The mechanism, and the bench equilibration that prevents it, is laid out in the storage guide linked above; the short version is that a sealed vial reaches room temperature before it opens, every time, with twenty to thirty minutes on the bench usually enough for a small vial.
The second is casualness about solutions. A powder with a tough reputation produces solutions that get stretched, held past any defensible window, and left undated because nobody worries about them. The chemistry does not honour the reputation. Once water is present, hydrolysis and aspartate isomerization run at their own rates, and whatever was introduced at preparation grows on its own schedule. The vial has not read its own literature; it degrades on chemistry's timetable, not the marketing's.
Solution preparation arithmetic, gross and net
Both stocked sizes work through the same arithmetic. A 10 mg vial brought into 2 mL of diluent gives
10 mg ÷ 2 mL = 5 mg/mL
and the 5 mg size into 1 mL lands at the same concentration:
5 mg ÷ 1 mL = 5 mg/mL
The wrinkle worth documenting is gross mass against net peptide content. Research peptides ship as salts, most commonly acetate, and counterions plus residual water count toward the label figure. Where the certificate of analysis states net peptide content, careful arithmetic starts from it:
10 mg × 0.85 net = 8.5 mg
8.5 mg ÷ 2 mL = 4.25 mg/mL
A record stating 5 mg/mL on a gross basis and one stating 4.25 mg/mL on a net basis describe the same vial. Neither is wrong; a record that does not say which basis it used is. The vial concentration calculator handles other vial sizes and volumes, and the cost-per-milligram tool is the fair way to compare the two sizes, since the larger vial tends to carry the lower per-milligram figure. Current sizes and pricing sit on the BPC 157 product record.
Diluent choice follows the same logic as for any peptide: a preserved diluent where the container will be entered more than once, plain sterile water for single-session work, with the full argument in the BAC water guide. BPC 157 dissolves readily in water, and no benzyl-alcohol incompatibility specific to this compound is documented in sources this page would trust. The observational rule from that guide still applies, though: a solution that clouds has answered the question by itself, and the answer is plain water and single-use aliquots.
Documentation and certificate literacy
Because no monograph defines this material, the certificate of analysis does more work than usual. Identity should rest on a mass-spectrometric measurement consistent with the expected mass near 1419 daltons for the free peptide, stated with its method and date. Purity should be a chromatographic area percentage from RP-HPLC, again with the method named. Net peptide content, where reported, is a separate assay answering a separate question, and a certificate presenting one bare number with no method behind any of them is a formatting exercise rather than evidence. What a competent supplier commits to documenting is described in the quality standard.
The preparation record is the laboratory's half of the same discipline. At minimum it carries the source lot identifier, the diluent and its lot, the volume added, the resulting concentration and the basis it was computed on, the date and time of preparation, and the initials of the preparer. Aliquots inherit the record through a shared identifier written on each tube.
The reason is practical. When a result reads wrong months later, the first question is whether the material was what the protocol assumed, and a chain running from aliquot to solution to lot to certificate answers it in a minute. A gap anywhere in that chain means repeating the work, which is a long way to rediscover the price of an unlabelled tube.
Regulatory position
BPC 157 appears in a preclinical research literature. No FDA-approved product contains it, and no USP/NF monograph defines what an acceptable article of the substance is.
Its compounding status has moved twice. The FDA placed BPC 157 in Category 2 of the 503A bulk drug substances list, the category for substances that may present significant safety risks, effective with the agency's update of 29 September 2023. In April 2026 the agency removed it from Category 2 after the nomination supporting the listing was withdrawn. Removal did not place the substance in Category 1 or add it to the bulks permitted for 503A compounding, and BPC-157-related substances were before the Pharmacy Compounding Advisory Committee again on 23 July 2026. Anyone relying on this status should check the current list rather than a supplier's summary, including this one.
Status verified 25 August 2026.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Common questions
Does lyophilized BPC 157 need a freezer?
How long does a prepared BPC 157 solution keep?
Is BPC 157 really more stable than other peptides?
Can a BPC 157 solution be refrozen after thawing?
Why does the certificate show less than 10 mg of peptide in a 10 mg vial?
Does BPC 157 have an official expiry date?
Sources
- PubChem compound record for BPC 157. Sequence and molecular mass of the free peptide; supports the fifteen-residue composition the degradation-route table is read against.
- FDA 503A bulk drug substances list and Pharmacy Compounding Advisory Committee materials, 2023–2026. Category 2 placement effective 29 September 2023, the April 2026 removal after nomination withdrawal, and the 23 July 2026 committee review.
- Originating preclinical literature on BPC 157 (Sikiric and colleagues). Source of the reported gastric-juice stability claim; described generically because the claim is treated here as a reported finding from the group that introduced the compound, not as established shelf-life data.
- Review literature on stability of lyophilized peptides and proteins. General degradation routes, the primacy of moisture control, and freeze-thaw aggregation; described generically because no single paper is load-bearing for these points.